An interventional study of bioptron light therapy in Dysmenorrhea Primary and Obesity and Overweight, sponsored by Alaa Noureldeen Kora. Not yet recruiting at 1 site in Egypt. Open to female participants aged 16 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Alaa Noureldeen Kora · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Obesity with a site in Egypt — 32 open to participants now, 39 under way, none of them phase 3. Obesity · Egypt.
Among the 138 studies in Obesity with a site in Egypt, this one is the 18th largest by planned enrollment of the 102 interventional ones that give a count, is one of 23 that started in 2025, is one of 90 with no phase, reaches primary completion later than 19 of the 38 other live ones, and was the 96th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →32 of the 138 studies in Obesity with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 60–70 · Women only
Badr University · Sites in Egypt
Ages 36–58
Cairo University · Sites in Egypt
Ages 40–55
Cairo University · Sites in Egypt
Ages 18–60
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 16 Years to 18 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 2006; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 60 across the 102 interventional studies, 100 across the 36 observational. Of the 87 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 138 have an industry lead sponsor. The 10 most frequent:
Alaa Noureldeen Kora is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Alaa Noureldeen Kora has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
7 of the studies in Obesity with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07397572Cairo UniversityIron Supplementation and Anemia After Sleeve Gastrectomy | 2026-11 |
| NCT06901440Assiut UniversityBariatric Surgery for Obesity | 2026-12 |
| NCT07336797Abdelrahman MahmoudEffect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy | 2026-12-30 |
| NCT07683286Cairo UniversityPilates Exercises Versus Intermittent Fasting Diet on Physical and Metabolic Aging Process in Obese Perimenopausal Women | 2027-01-01 |
| NCT07857395Zagazig UniversityModified El-Ganzouri Risk Index for Predicting Difficult Intubation in Obese Patients | 2027-03-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 138 studies in Obesity with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dysmenorrhea is the most common health problem in women in the reproductive age(Bakhsh et al., 2022). The primary dysmenorrhea starts shortly after the menarche the pain lasting 1 to 3 days that start just before or at the onset of menstruation with the absence of other gynecological symptoms (Itani et al., 2022). Primary dysmenorrhea can reduce the quality of life and social activities of women(Esan et al., 2024).
There is a relationship between body mass composition and primary dysmenorrhea and as the value of body mass index and body fat percentages goes on increasing in females, the severity of primary dysmenorrhea also increased (Wu et al., 2022).
BIOPTRON® Light therapy system is a device that contains an optical unit. This unit emits light with an electromagnetic spectrum produced by the sun, but without the ultraviolet rays and it is significant with four main characteristics which are Polarization, Polychromatic, Incoherence and low energy light (Raeissadat et al., 2014).
The Purpose of the Study The aim of the study is to investigate the effect of bioptron© light therapy on primary dysmenorrhoea outcomes as pain and quality of life among obese adolescence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: bioptron light therapy
Device: bioptron light therapy
BIOPTRON® Hyperlight is a proprietary, optimized blend of visible and infrared light properties that Bio-stimulate cells and speeding up the healing process of a wide range of medical diseases. Bioptron© light therapy has been utilized as a non-invasive treatment for wound healing, skin ulcers, and various musculoskeletal conditions(Abd Elhamid et al., 2020).
number of anatomical pain locations, pain range, number of days of pain during menstruation (and frequency of disabling pain to perform their activities.
Time frame: At the end of Cycle 1 (each cycle is 28 days)".
Numerical Rating Scale (NRS): is a single-item question that asks the patient to rate the pain on a scale of 0 to 10.
Time frame: At the end of Cycle 1 (each cycle is 28 days)".
Algometer is an objective measurement of the degree of pressure required to evoke a painful response over selected trigger points.
Time frame: At the end of Cycle 1 (each cycle is 28 days)".
The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure health-related quality of life.
Time frame: At the end of Cycle 1 (each cycle is 28 days)".
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Aug 2025, 0 months later.
Of 3,690 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 0 months is below that.
Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alaa Noureldeen Kora